Short‐term effect of low‐dose rituximab on myasthenia gravis with muscle‐specific tyrosine kinase antibody

Abstract

We confirmed the clinical efficacy of low-dose rituximab in MuSK-MG, accompanied by a decrease in MuSK antibody titers and an increase in serum BAFF. Serum BAFF levels negatively correlated with B-cell counts as well as clinical severity.